CHILL NOT KILL

What this means for you

Not registered yet, but its 30 Sept 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

99420419

Mark type

Stylized text

Filed

30 Sept 2025

Attorney of record

Dmitriy Makarov

Goods and services

• Class 001 — Chemicals: Chemical and biological preparations for use in science and industry, other than for medical or veterinary use; chemical and biological preparations for non-medical and non-veterinary purposes, namely, for scientific purposes; chemical and biological preparations for genetically modifying human and animal cells other than for medical or veterinary purposes; chemical and biological reagents for use in the genetic modification of human and animal cells other than for medical or veterinary purposes; human and animal cells and parts thereof, namely, cell receptors, cell surface markers, and transcription factors for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; biological tissue, namely, blood and cells extracted from humans and animals for scientific and research purposes; immunological agents and preparations in the nature of transduced human and animal cells, for non-medical purposes; biological preparations in the nature of chimeric antigen receptors and preparations thereof for scientific and research purposes other than for medical or veterinary purposes; antibody reagents used for the detection of antigens in cells and tissue and for the proliferation and homing of cells for use in science and industry, other than for medical or veterinary purposes; nucleic acids for scientific purposes; nucleic recombinant acids for scientific purposes; biological preparations in the nature of synthetic deoxyribonucleic acids for use in science and industry, other than for medical or veterinary use; viral vectors for research purposes for use in science and industry; viral and non-viral nucleic acid vectors for research purposes for use in science and industry
• Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use for the treatment and prevention of immune-mediated diseases; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes for the treatment and prevention of immune-mediated diseases; pharmaceutical preparations for cell therapy for the treatment and prevention of immune-mediated diseases; pharmaceutical preparations for gene therapy for the treatment and prevention of immune-mediated diseases; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes for the treatment and prevention of immune-mediated diseases; living human and animal cells for medical and veterinary purposes; living T cells for medical and veterinary purposes; living regulatory T cells for medical and veterinary purposes; blood and living cells extracted from humans and animals which have been adapted for therapeutic medical purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system for the treatment and prevention of immune-mediated diseases; pharmaceutical immunological agents and preparations affecting the immune system for medical purposes; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; biological preparations in the nature of chimeric antigen receptors and therapeutic preparations thereof for the treatment and prevention of immune-mediated diseases; antibodies for medical purposes; pharmaceutical preparations for therapeutic delivery of nucleic acids for the treatment and prevention of immune-mediated diseases; pharmaceutical preparations in the nature of viral vectors for therapeutic and prophylactic purposes for the treatment and prevention of immune-mediated diseases; biological preparations in the nature of nucleic acid vectors for therapeutic and prophylactic purposes for the treatment and prevention of immune-mediated diseases; medical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment and prevention of immune-mediated diseases; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment and prevention of immune-mediated diseases
• Class 040 — Treatment of materials: Biomanufacturing services for others in the field of pharmaceuticals, namely, biomanufacturing and processing services for others in the field of pharmaceuticals; biomanufacturing services for others in the field of pharmaceuticals, namely, biological, biotechnological and biopharmaceutical manufacturing and processing for others; biological tissue, blood, cell and genetic material processing; biomanufacturing services for others in the field of pharmaceuticals, namely, viral vector production and manufacture; biomanufacturing services for others in the field of pharmaceuticals, namely, gene therapy production and manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products

Owner

• Quell Therapeutics Limited, London, GB

Prosecution history

• 10 Sept 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 10 Sept 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 26 Aug 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 26 Aug 2026 — NON-FINAL ACTION E-MAILED
• 26 Aug 2026 — NON-FINAL ACTION WRITTEN
• 03 Aug 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 03 Aug 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 03 Aug 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 30 Apr 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 30 Apr 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 05 Feb 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 05 Feb 2026 — NON-FINAL ACTION E-MAILED
• 05 Feb 2026 — NON-FINAL ACTION WRITTEN
• 04 Feb 2026 — ASSIGNED TO EXAMINER
• 30 Sept 2025 — APPLICATION FILING RECEIPT MAILED